Bradykinin (acetate)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Bradykinin (acetate) is a well-known 9-amino acid endogenous vasoactive peptide and a systemic vasodilator [1].
Bradykinin is a potent endothelium-dependent vasodilator, leading to the reduction in blood pressure. It also induces contraction of non-vascular smooth muscle in the bronchus and gut, increases vascular permeability and is also involved in the mechanism of pain. Bradykinin is an inflammatory mediator. The Bradykinin B1 receptor is expressed only as a result of tissue injury and plays a role in inflammation. The Bradykinin B2 receptor is constitutively expressed and participates in bradykinin's vasodilatory role.
In cultured endothelial cells, bradykinin promoted a rapid dissociation of the eNOS:B2 receptor complex [2]. In the mouse gastrointestinal tract and pancreas, bradykinin stimulated extravasation from postcapillary venules by two- to sevenfold by interacting with B2 receptors and stimulating tachykinin release from sensory nerves [3].
In healthy men, bradykinin (100-3200 ng/kg min) dose-related increased plasma concentrations of 6-oxo-PGF1a , the stable hydrolysis product of prostacyclin (PGI2). So bradykinin may have a use as a probe of PG12 production in vivo in pathological states [1].
References:
[1]. Barrow SE, Dollery CT, Heavey DJ, et al. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol. 1986 Jan;87(1):243-7.
[2]. Ju H, Venema VJ, Marrero MB, et al. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem. 1998 Sep 11;273(37):24025-9.
[3]. Figini M, Emanueli C, Grady EF, et al. Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas. Am J Physiol. 1997 Apr;272(4 Pt 1):G785-93.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 1120.3 |
Cas No. | 6846-03-3 |
Formula | C50H73N15O11·XC2H4O2 |
Synonyms | H 1970 |
Solubility | ≥113 mg/mL in DMSO with gentle warming; ≥113.5 mg/mL in EtOH with gentle warming; ≥226.6 mg/mL in H2O |
Chemical Name | (S)-2-((S)-2-((S)-1-((S)-2-((S)-2-(2-((S)-1-((S)-1-((S)-2-amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)-5-guanidinopentanoic a |
SDF | Download SDF |
Canonical SMILES | O=C([C@H](CCC1)N1C([C@@H](N)CCCNC(N)=N)=O)N(CCC2)[C@@H]2C(NCC(N[C@H](C(N[C@@H](CO)C(N(CCC3)[C@@H]3C(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CC=CC=C5)=O)=O.CC(O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines |
Human umbilical vein endothelial cells and monocytes |
Reaction Conditions |
10-8 ~ 10-5 mol/l bradykinin for 1 h pretreatment |
Applications |
Exogenous bradykinin markedly inhibited tissue factor expression in mRNA and protein level induced by lipopolysaccharides in a dose-dependent manner. |
Animal experiment:[1] | |
Animal models |
C57/BL6 mice |
Dosage form |
10 mg/kg/d Injected intraperitoneally for 3 days ahead of inferior cava vein ligation and for another 2 days after surgical procedure |
Applications |
Intraperitoneal injection of C57/BL6 mice with bradykinin inhibited the thrombus formation induced by ligation of inferior vena cava. |
Note |
The technical data provided above is for reference only. |
References: 1. Dong R, Chen W, Feng W, et al. Exogenous bradykinin inhibits tissue factor induction and deep vein thrombosis via activating the eNOS/phosphoinositide 3-kinase/Akt signaling pathway. Cellular Physiology and Biochemistry, 2015, 37(4): 1592-1606. |
质量控制和MSDS
- 批次: